News and Press Releases
Inflammatory Bowel Disease (IBD)
-
Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease
September 2022
-
Tucson startup looks to human trials for drug to treat lung inflammation
Jan 2022
-
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
January 2022
-
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase
Dec 2021
-
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition
August 2021
-
Healing lungs, improving data, oncology research and more
June 2020